Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Rubinstein-Taybi Syndrome 1Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 27Docetaxel 20Cyclophosphamide 18Surveys and Questionnaires 15Therapeutics 14Radiotherapy 13Paclitaxel 12Psychiatric Rehabilitation 11Early Intervention, Educational 11Carboplatin 11Standard of Care 10olaparib 9Zoledronic Acid 9Specimen Handling 9Radiosurgery 9Magnetic Resonance Spectroscopy 9Interviews as Topic 9Gemcitabine 9Trastuzumab 8Methods 8Fulvestrant 8palbociclib 7fludarabine 7durvalumab 7Taxes 7Nivolumab 7Fluorodeoxyglucose F18 7Flow Cytometry 7Educational Status 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × mocetinostat × Genitourinary × Clear all
NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Mirati Therapeutics Inc.

Phase 1 Terminated
54 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡